• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Bakshi Rajeev Kumar

    2/27/25 5:51:37 PM ET
    $ACOG
    Get the next $ACOG alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    BAKSHI RAJEEV KUMAR

    (Last) (First) (Middle)
    C/O ALPHA COGNITION INC.
    1200 - 750 WEST PENDER STREET

    (Street)
    VANCOUVER A1 V6C 2T8

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Alpha Cognition Inc. [ ACOG ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    02/25/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Common Share Options $5.93 02/25/2025 A 38,762 (1) 02/25/2035 Common Shares 38,762 $0 38,762 D
    Explanation of Responses:
    1. The options will vest over 24 months, with 12.5% vesting on the grant date and remainder to vest 12.5% per quarter thereafter.
    Rajeev Baskhi 02/27/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ACOG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACOG

    DatePrice TargetRatingAnalyst
    3/18/2025$20.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACOG
    Financials

    Live finance-specific insights

    See more
    • Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview

      Conference Call Scheduled for May 15, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today will announce financial results for the first quarter ended March 31, 2025 on May 15, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: 1-877-407-9039 or 1-201-689-8470 Note, you can avoid long wait times for the operator by using the Call me™ feature and clicking the link below 15 minutes prior to the schedul

      5/1/25 8:30:00 AM ET
      $ACOG
    • Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

       Raised $52.8 million in gross proceeds in Q4 2024 to support the upcoming ZUNVEYL commercial launch and Nasdaq uplisting (symbol: ACOG). Completed commercial manufacturing to support the ZUNVEYL launch. Successfully completed the first phase of a pre-clinical bomb-blast study funded by a Department of Defense grant, demonstrating benzgalantamine's efficacy and safety in treating head trauma from simulated bomb blasts. Cash and cash equivalents of $48.6 million as of December 31, 2024, compared to $3.7 million as of September 30, 2024 and $1.4 million as of December 31, 2023. At current cash utilization rates, the Company expects a cash runway of approximately two years. Alpha Cogn

      3/31/25 8:30:00 AM ET
      $ACOG
    • Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

      Conference Call Scheduled for March 31, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2024 on March 31, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: 1-877-407-9039 or 1-201-689-8470 Note, you can avoid long wait times for the operator by using the Call me™ feature and clicking the lin

      3/19/25 4:30:00 PM ET
      $ACOG

    $ACOG
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ACOG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ACOG
    SEC Filings

    See more

    $ACOG
    Leadership Updates

    Live Leadership Updates

    See more
    • Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview

      Conference Call Scheduled for May 15, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today will announce financial results for the first quarter ended March 31, 2025 on May 15, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: 1-877-407-9039 or 1-201-689-8470 Note, you can avoid long wait times for the operator by using the Call me™ feature and clicking the link below 15 minutes prior to the schedul

      5/1/25 8:30:00 AM ET
      $ACOG
    • Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer's Association International Conference

      Alpha Cognition Inc. (NASDAQ:ACOG) (the "Company" or "Alpha Cognition") today announced three upcoming presentations at the 2025 Alzheimer's Association International Conference (the "AAIC"), taking place July 27–31, 2025 in Toronto, Canada. The presentations will highlight clinical studies supporting ZUNVEYL (benzgalantamine), the Company's lead product and a novel galantamine prodrug approved by the FDA in July 2024 and commercially launched in March 2025. The studies demonstrated bioequivalence to galantamine IR and ER and were integral to the NDA submission and approval. "We're excited to share data that underscore ZUNVEYL's potential to deliver meaningful clinical benefit to patients

      4/28/25 8:30:00 AM ET
      $ACOG
    • Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

      4/10/25 8:30:00 AM ET
      $ACOG
      $CBAY
      $MIST
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Alpha Cognition with a new price target

      H.C. Wainwright initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $20.00

      3/18/25 7:48:36 AM ET
      $ACOG
    • SEC Form DEF 14A filed by Alpha Cognition Inc.

      DEF 14A - Alpha Cognition Inc. (0001655923) (Filer)

      4/30/25 4:30:51 PM ET
      $ACOG
    • Alpha Cognition Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Alpha Cognition Inc. (0001655923) (Filer)

      4/10/25 4:40:34 PM ET
      $ACOG
    • SEC Form 10-K filed by Alpha Cognition Inc.

      10-K - Alpha Cognition Inc. (0001655923) (Filer)

      3/31/25 4:01:52 PM ET
      $ACOG
    • Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

      4/10/25 8:30:00 AM ET
      $ACOG
      $CBAY
      $MIST
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; Rommel Fernandez, Vice President of Corporate Strategy and Operations; and Kurt Grady, Vice President of Medical Affairs. These hires mark significant milestones in building Alpha Cognition's commercial and medical teams as the company prepares for the upcoming launch of ZUNVEYL, its innovative treatment for mild to moderate Alzheimer's disease. Ms. Pesa brings 25 years of pharmaceutic

      1/14/25 8:30:00 AM ET
      $ACOG

    $ACOG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Havens John Prentiss

      4 - Alpha Cognition Inc. (0001655923) (Issuer)

      4/29/25 4:41:09 PM ET
      $ACOG
    • SEC Form 4 filed by Director Wills Robert James

      4 - Alpha Cognition Inc. (0001655923) (Issuer)

      4/9/25 9:44:29 PM ET
      $ACOG
    • SEC Form 3 filed by new insider Wills Robert James

      3 - Alpha Cognition Inc. (0001655923) (Issuer)

      4/9/25 9:24:20 PM ET
      $ACOG